Hans Biomed한스바이오메드
042520 · KOSDAQ · ₩042520 · 한스바이오메드
- Market cap
- ₩244B
- Enterprise value
- ₩266B
- P/E
- —
- P/B
- 3.3×
- Dividend yield
- 0.0%
- ROE
- −33.5%
- Net margin
- −22.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−70.4% from the high
₩15,300Today: ₩17,110 – ₩17,600₩57,800
Returns
- 1W−9.9%
- 1M−3.8%
- 3M−8.4%
- 6M−45.0%
- YTD−38.0%
- 1Y−48.6%
- Volume today
- 61,683
- 0.5× the 20-day average
- Traded today
- ₩1.1B
- Listed shares
- 14,261,367
- EPS (12 months)
- −₩1,742
- Earnings yield −10.2%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 32 of 100 (50 is a normal day for this stock).
- MomentumFlat-1.2% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Hans Biomed stock overview
Hans Biomed (한스바이오메드, KRX: 042520) is listed on KOSDAQ, in the Biotech & Pharma sector. The company was founded in 1999 and researches, manufactures and sells human tissue grafts for skin and bone, along with medical devices. Its shares closed at ₩17,110 on Oct 27, 2026, up 0.47% on the day, giving it a market value of ₩244B.
Key facts
- Market cap
- ₩244B
- Sector
- Biotech & Pharma
- Latest price change
- +0.47%
- As of
- Oct 27, 2026
- Main business
- The company was founded in 1999 and researches, manufactures and sells human tissue grafts for skin and bone, along with medical devices.
Quick answers about Hans Biomed
- What does Hans Biomed do?
- The company was founded in 1999 and researches, manufactures and sells human tissue grafts for skin and bone, along with medical devices. Its main products include skin graft products such as Bella Cell HD and bone graft products such as SureFuse, medical devices such as MintLift and hair transplant devices, and it also generates silicone-material sales and rental income. It operates its headquarters and domestic affiliates in Songpa-gu, Seoul, with research and production facilities in Daejeon, and sells to hospitals in Korea and overseas through distributors, including subsidiaries in the United States, Thailand and the United Kingdom.
- What is the market cap of Hans Biomed?
- The market capitalisation of Hans Biomed was ₩244B at the close on Oct 27, 2026.
- Who are the largest shareholders of Hans Biomed?
- According to the latest official filings, the largest reported holders are Hwang Ho-chan (23.95%, as of Dec 12, 2025); Neo Young (5.58%, as of Jun 9, 2026); Tiger Asset Management Discretionary Investment (5.44%, as of Sep 3, 2026).
- When is the next earnings report from Hans Biomed?
- Korean companies rarely announce results dates in advance. Based on when Hans Biomed filed the same report in past years, its next annual results is expected between Dec 18, 2026 and Dec 20, 2026.
- Does the National Pension Service own Hans Biomed?
- Yes. The National Pension Service held 4.88% of Hans Biomed shares as of Oct 2, 2026.
Company profile
The company was founded in 1999 and researches, manufactures and sells human tissue grafts for skin and bone, along with medical devices. Its main products include skin graft products such as Bella Cell HD and bone graft products such as SureFuse, medical devices such as MintLift and hair transplant devices, and it also generates silicone-material sales and rental income. It operates its headquarters and domestic affiliates in Songpa-gu, Seoul, with research and production facilities in Daejeon, and sells to hospitals in Korea and overseas through distributors, including subsidiaries in the United States, Thailand and the United Kingdom.
Written by AI from the company's latest annual report.
- Korean name
- 한스바이오메드
- Sector
- Biotech & Pharma
- Themes
- Medical devices
- CEO
- 김근영
- Founded
- Sep 1999
- Listed
- Oct 2009
- Listed shares
- 14,261,367
- Fiscal year ends
- Month 09
- Website
- hansbiomed.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- 5%+ holding reportOct 2, 2026
- Determination of Shareholder Register Closure Period or Record DateSep 15, 2026
- 5%+ holding reportSep 3, 2026
- 5%+ holding reportSep 2, 2026
- Quarterly report (Jun 2026)Aug 13, 2026
Titles in Korean until English translations are added.
Also known as: Hans Biomed / 한스바이오메드 / 042520 / KRX:042520
Source: KRX statistical information